Di Pasqua L, Cagna M, Berardo C, Vairetti M, Ferrigno A
Biomedicines. 2022; 10(1).
PMID: 35052872
PMC: 8774221.
DOI: 10.3390/biomedicines10010194.
Prakash P, Sayyed-Ahmad A, Zhou Y, Volk D, Gorenstein D, Dial E
Biochim Biophys Acta. 2012; 1818(12):3040-7.
PMID: 22885171
PMC: 3478136.
DOI: 10.1016/j.bbamem.2012.07.029.
Rainsford K
Inflammopharmacology. 2009; 17(6):275-342.
PMID: 19949916
DOI: 10.1007/s10787-009-0016-x.
Smith C, RajanBabu T
J Org Chem. 2009; 74(8):3066-72.
PMID: 19317393
PMC: 2748116.
DOI: 10.1021/jo900198b.
Yoon J, Jeong D, Oh J, Lee K, Lee H, Koh Y
Br J Clin Pharmacol. 2008; 66(6):854-60.
PMID: 19032727
PMC: 2675775.
DOI: 10.1111/j.1365-2125.2008.03271.x.
Chiral inversion of (R)-(-)-fenoprofen in guinea-pigs pretreated with clofibrate.
San Martin M, Soraci A, Fogel F, Tapia O, Islas S
Vet Res Commun. 2002; 26(4):323-32.
PMID: 12184503
DOI: 10.1023/a:1016046810103.
Chiral inversion of (R)-ketoprofen: influence of age and differing physiological status in dairy cattle.
Igarza L, Soraci A, Auza N, Zeballos H
Vet Res Commun. 2002; 26(1):29-37.
PMID: 11860085
DOI: 10.1023/a:1013301620904.
Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen.
Evans A
Clin Rheumatol. 2002; 20 Suppl 1:S9-14.
PMID: 11771573
DOI: 10.1007/BF03342662.
Efficacy and long-term safety of dexibuprofen [S(+)-ibuprofen]: a short-term efficacy study in patients with osteoarthritis of the hip and a 1-year tolerability study in patients with rheumatic disorders.
Mayrhofer F
Clin Rheumatol. 2002; 20 Suppl 1:S22-9.
PMID: 11771571
DOI: 10.1007/BF03342664.
Clinical pharmacokinetics of dexketoprofen.
Barbanoj M, Antonijoan R, Gich I
Clin Pharmacokinet. 2001; 40(4):245-62.
PMID: 11368291
DOI: 10.2165/00003088-200140040-00002.
Clinical pharmacokinetics of ibuprofen. The first 30 years.
Davies N
Clin Pharmacokinet. 1998; 34(2):101-54.
PMID: 9515184
DOI: 10.2165/00003088-199834020-00002.
Preclinical and clinical development of dexketoprofen.
Mauleon D, Artigas R, Garcia M, Carganico G
Drugs. 1996; 52 Suppl 5:24-45; discussion 45-6.
PMID: 8922555
DOI: 10.2165/00003495-199600525-00005.
Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations.
Li G, Treiber G, Maier K, Walker S, Klotz U
Clin Pharmacokinet. 1993; 25(2):154-63.
PMID: 8403739
DOI: 10.2165/00003088-199325020-00008.
Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans.
Cheng H, Rogers J, Demetriades J, Holland S, Seibold J, DePuy E
Pharm Res. 1994; 11(6):824-30.
PMID: 7937520
DOI: 10.1023/a:1018969506143.
Nonsteroidal anti-inflammatory drugs in perisurgical pain management. Mechanisms of action and rationale for optimum use.
Cashman J, McAnulty G
Drugs. 1995; 49(1):51-70.
PMID: 7705216
DOI: 10.2165/00003495-199549010-00005.
Influence of probenecid on the urinary excretion rates of the diastereomeric benoxaprofen glucuronides.
Spahn H, Iwakawa S, Bevet L, Lin E
Eur J Drug Metab Pharmacokinet. 1987; 12(4):233-7.
PMID: 3449380
DOI: 10.1007/BF03189905.
Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs.
Jamali F
Eur J Drug Metab Pharmacokinet. 1988; 13(1):1-9.
PMID: 3294019
DOI: 10.1007/BF03189920.
Pharmacokinetics of S(+)- and R(-)-ibuprofen in volunteers and first clinical experience of S(+)-ibuprofen in rheumatoid arthritis.
Geisslinger G, Schuster O, Stock K, Loew D, BACH G, Brune K
Eur J Clin Pharmacol. 1990; 38(5):493-7.
PMID: 2379535
DOI: 10.1007/BF02336690.
Clinical pharmacokinetics of ketoprofen and its enantiomers.
Jamali F, Brocks D
Clin Pharmacokinet. 1990; 19(3):197-217.
PMID: 2203580
DOI: 10.2165/00003088-199019030-00004.
Stereoselectivity in clinical pharmacokinetics and drug development.
Campbell D
Eur J Drug Metab Pharmacokinet. 1990; 15(2):109-25.
PMID: 2200681
DOI: 10.1007/BF03190194.
